Screener / SEC EDGAR /CIK 0001576280 /10-K filed Feb 19, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Labs

Guardant Health, Inc. GH

Compare with peers Embed
FY2025 at a glance

Sales up 32.9%, free cash flow up to -$233.1M

XBRL, from each 10-K
RevenueStatements
$982.0M from $739.0M in FY2024
FY2016FY2025
Net incomeStatements
-$416.3M from -$436.4M in FY2024
FY2016FY2025
Free cash flowStatements
-$233.1M from -$274.9M in FY2024
FY2016FY2025
EPS (diluted)Statements
$-3.32 from $-3.56 in FY2024
FY2016FY2025
Operating marginStatements
-44.5% from -60.0% in FY2024
FY2016FY2025
Total debtStatements
$1.5B from $1.1B in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (40)
EPS (ttm)
-3.68
Sales (ttm)
1.3B
Net income (ttm)
-485.1M
Sales growth
+32.9%
EPS growth
-
Sales Q/Q
+36.1%
Free cash flow
-232.1M
Gross margin
65.2%
Oper. margin
-39.4%
Net margin
-37.9%
FCF margin
-18.2%
ROE
n/m
R&D / sales
37.1%
Dividend
-
Debt/Eq
n/m
Curr. ratio
3.60
Cash
1.0B
Op. cash flow (ttm)
-173.5M
EBITDA
-397.5M
EBITDA margin
-40.5%
Net debt
475.6M
Quick ratio
3.37
Interest cover
-112.20
FCF after stock pay
-399.3M
Goodwill / assets
3.8%
Oper. margin low 5y
-121.1%
Stock pay / sales
16.9%
Shares out.
135.3M
Shares Y/Y
+2.1%
Book / share
-2.04
Cash / share
7.59
Sales / share
9.45
Asset turnover
0.68
Inventory turns
4.06
Days sales out.
51
Sales 3Y CAGR
+29.7%
Sales 5Y CAGR
+27.9%
Employees
2,506
Sales / employee
510K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 982.0M +50.2% a year Net income -416.3M
FY2016 revenue 25.2M · Revenues, 0001628280-19-003139 FY2016 net income -46.1M · NetIncomeLoss, 0001628280-19-003139 25.2M FY2016 FY2017 revenue 49.8M · Revenues, 0001628280-20-002613 FY2017 net income -83.2M · NetIncomeLoss, 0001628280-20-002613 49.8M FY2017 FY2018 revenue 90.6M · Revenues, 0001576280-21-000031 FY2018 net income -85.1M · NetIncomeLoss, 0001628280-20-002613 90.6M FY2018 FY2019 revenue 214.4M · Revenues, 0001576280-22-000015 FY2019 net income -75.7M · NetIncomeLoss, 0001628280-20-002613 214.4M FY2019 FY2020 revenue 286.7M · Revenues, 0001576280-23-000020 FY2020 net income -253.8M · NetIncomeLossAvailableToCommonStockholdersBasic, 0001576280-23-000020 286.7M FY2020 FY2021 revenue 373.7M · Revenues, 0001576280-24-000043 FY2021 net income -384.8M · NetIncomeLoss, 0001576280-24-000043 373.7M FY2021 FY2022 revenue 449.5M · Revenues, 0001576280-25-000044 FY2022 net income -654.6M · NetIncomeLoss, 0001576280-25-000044 449.5M FY2022 FY2023 revenue 563.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001576280-26-000013 FY2023 net income -479.4M · NetIncomeLoss, 0001576280-26-000013 563.9M FY2023 FY2024 revenue 739.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001576280-26-000013 FY2024 net income -436.4M · NetIncomeLoss, 0001576280-26-000013 739.0M FY2024 FY2025 revenue 982.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001576280-26-000013 FY2025 net income -416.3M · NetIncomeLoss, 0001576280-26-000013 982.0M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $1.5B
  • − All liabilities $2.1B
  • = Net current asset value -$646.9M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $99.3M
  • − Goodwill $77.3M
  • − Other intangible assets $25.9M
  • = Tangible book value -$202.5M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

GH against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+32.9%27th of 155 · median +10.5%
Net margin
-4.1%15.3%
-37.9%135th of 154 · median 6.8%
Free cash flow margin
2.3%19.2%
-18.2%124th of 145 · median 10.0%
GH and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
GH Guardant Health, Inc.$1.3B +32.9%65.2%-37.9%--18.2%-
HAE Haemonetics Corp$1.4B -2.0%59.6%7.5%11.6%21.6%1.27
PGNY Progyny, Inc.$1.3B +10.4%24.9%6.8%22.0%13.4%-
SHC Sotera Health Co$1.2B +5.7%54.6%14.1%23.7%11.0%2.91
TECH Bio-Techne$1.2B -0.4%65.8%14.0%7.9%25.1%0.18
ACAD Acadia Pharmaceuticals Inc$1.2B +11.9%90.5%30.1%26.1%6.8%-
All 162 companies in the group

Where the $982.0M of revenue came from

by product, year to Dec 31, 2025

  • Oncology $683.6M · 70%
  • Biopharma and data $210.1M · 21%
  • Screening $79.7M · 8%
  • Licensing and other $8.6M · 1%

From the segment tables in the 10-K XBRL.

Profitability

  • Net margin below the peer median
    -37.9% vs 6.8%
  • A profit in 0 of 10 years
Net margin, FY2016 to FY2025: -182.7% to -42.4%

Balance sheet

  • Interest covered less than 5 times
    Operating income is -112.2× interest expense
  • Equity below zero
    Debt $1.5B, equity −$275.9M
  • Current assets cover current liabilities
    Current ratio 3.60
  • More cash than debt
    Net cash $347.8M

Cash and shareholders

  • Free cash flow positive in 0 of 10 years
    −$233.1M last year
  • Share count up over 5 years
    +28.6%
Free cash flow, FY2016 to FY2025: -38.5M to -233.1M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Contract liabilities

Paid in advance $45.1M cash received before delivery, not yet recognized as revenue, Sep 30, 2026 · -20.0% on a year earlier

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

GH's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue982.0M
FY2016: 25.2MFY2017: 49.8MFY2018: 90.6MFY2019: 214.4MFY2020: 286.7MFY2021: 373.7MFY2022: 449.5MFY2023: 563.9MFY2024: 739.0MFY2025: 982.0M FY2017FY2019FY2021FY2023FY2025
Net income-416.3M
FY2016: -46.1MFY2017: -83.2MFY2018: -85.1MFY2019: -75.7MFY2020: -253.8MFY2021: -384.8MFY2022: -654.6MFY2023: -479.4MFY2024: -436.4MFY2025: -416.3M FY2017FY2019FY2021FY2023FY2025
Free cash flow-233.1M
FY2016: -38.5MFY2017: -78.9MFY2018: -92.4MFY2019: -65.9MFY2020: -140.1MFY2021: -284.1MFY2022: -386.9MFY2023: -345.5MFY2024: -274.9MFY2025: -233.1M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay-399.3M
FY2016: -40.4MFY2017: -82.6MFY2018: -99.2MFY2019: -82.8MFY2020: -284.2MFY2021: -435.5MFY2022: -481.6MFY2023: -436.2MFY2024: -415.4MFY2025: -399.3M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)-3.32
FY2016: -3.53FY2017: -7.07FY2018: -2.80FY2019: -0.84FY2020: -2.60FY2021: -4.00FY2022: -6.41FY2023: -4.28FY2024: -3.56FY2025: -3.32 FY2017FY2019FY2021FY2023FY2025
Diluted shares125.4M
FY2016: -FY2017: -FY2018: -FY2019: 90.6MFY2020: 97.5MFY2021: 101.3MFY2022: 102.2MFY2023: 112.0MFY2024: 122.7MFY2025: 125.4M FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Oncology 683.6M69.6% +25.9%
Biopharma and data 210.1M21.4% +18.3%
Screening 79.7M8.1% +1456%
Licensing and other 8.6M0.9% -36.5%

10-K 0001576280-26-000013, segment and revenue notes (XBRL).

Revenue by region

year to Dec 31, 2025
RevenueSharevs year before
United States 923.3M94.0% +32.4%
International 58.7M6.0% +40.3%

10-K 0001576280-26-000013, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue25.2M49.8M90.6M214.4M286.7M373.7M449.5M563.9M739.0M982.0M
Cost of revenue-------227.1M289.8M349.0M
R&D10.9M25.6M50.7M86.3M149.9M263.2M373.8M367.2M347.8M364.2M
SG&A9.9M36.8M36.2M61.4M192.8M206.6M164.0M155.8M180.1M211.4M
Operating income-43.8M-76.6M-92.9M-82.4M-254.9M-411.0M-544.4M-564.7M-443.6M-437.2M
Interest expense3.0M2.7M1.3M1.2M4.8M2.6M2.6M2.6M2.6M3.9M
Pretax income-46.1M-83.2M-84.2M-69.7M-245.9M-384.5M-653.4M-478.8M-435.1M-417.5M
Income tax6K7K38K-1.9M379K300K1.1M685K1.3M-1.3M
Net income-46.1M-83.2M-85.1M-75.7M-253.8M-384.8M-654.6M-479.4M-436.4M-416.3M
EPS (diluted)-3.53-7.07-2.80-0.84-2.60-4.00-6.41-4.28-3.56-3.32
Diluted shares---90.6M97.5M101.3M102.2M112.0M122.7M125.4M
Depreciation & amortization3.7M5.2M7.1M11.4M16.1M22.3M36.0M42.9M42.4M39.7M
EBITDA-40.2M-71.4M-85.8M-71.0M-238.9M-388.7M-508.4M-521.8M-401.2M-397.5M
Operating margin-173.7%-153.7%-102.5%-38.4%-88.9%-110.0%-121.1%-100.1%-60.0%-44.5%
Net margin-182.7%-167.0%-93.8%-35.3%-88.5%-103.0%-145.6%-85.0%-59.0%-42.4%
Revenue growth-+97.4%+81.9%+137%+33.8%+30.3%+20.3%+25.5%+31.0%+32.9%

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-36.7M-72.2M-72.2M-47.1M-103.9M-209.0M-309.5M-325.0M-239.9M-184.8M
Capital spending1.8M6.7M20.2M18.7M36.2M75.0M77.5M20.5M35.1M48.3M
Free cash flow-38.5M-78.9M-92.4M-65.9M-140.1M-284.1M-386.9M-345.5M-274.9M-233.1M
Stock-based pay (added back)2.0M3.7M6.9M17.0M144.1M151.4M94.7M90.8M140.4M166.2M
Free cash flow after stock pay-40.4M-82.6M-99.2M-82.8M-284.2M-435.5M-481.6M-436.2M-415.4M-399.3M
Buybacks100K7.2M172K00--0045.0M
Acquisitions-007.3M00-0059.0M
Investing cash flow26.2M-170.4M-153.0M-317.6M-617.1M-63.2M149.8M840.2M-261.3M-627.2M
Financing cash flow39.8M281.7M293.2M367.3M1.4B-66.8M-189.1M477.4M-996K671.1M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)2.0M3.7M6.9M17.0M144.1M151.4M94.7M90.8M140.4M166.2M
Stock-based pay / revenue7.8%7.4%7.6%7.9%50.3%40.5%21.1%16.1%19.0%16.9%
Finance lease principal paid--443K127K174K146K71K---
Right-of-use assets--14.5M29.1M37.3M189.4M174.0M157.6M142.3M158.8M
Operating lease liabilities--22.4M40.4M48.2M238.9M231.9M213.8M193.5M206.1M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GH/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.